Holen Sie sich die Stockscreener-App
20.21
4.40%
-0.93
Handel nachbörslich:
20.21
Schlusskurs vom Vortag:
$21.14
Offen:
$21.19
24-Stunden-Volumen:
351.44K
Relative Volume:
0.42
Marktkapitalisierung:
$946.01M
Einnahmen:
$82.71M
Nettoeinkommen (Verlust:
$-102.24M
KGV:
-5.5068
EPS:
-3.67
Netto-Cashflow:
$-76.57M
1W Leistung:
-1.51%
1M Leistung:
-5.78%
6M Leistung:
+5.26%
1J Leistung:
+94.89%
1-Tages-Spanne:
$19.65
$21.20
1-Wochen-Bereich:
$19.65
$22.25
52-Wochen-Spanne:
$3.42
$30.00
Urogen Pharma Ltd Stock (URGN) Company Profile
Firmenname
Urogen Pharma Ltd
Sektor
Branche
Telefon
972 9 770 7601
Adresse
9 HA'TA'ASIYA ST, RA'ANANA
Compare URGN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
20.21 | 989.54M | 82.71M | -102.24M | -76.57M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-06-16 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-05-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-04-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-19 | Fortgesetzt | Ladenburg Thalmann | Buy |
| 2024-08-22 | Eingeleitet | Guggenheim | Buy |
| 2023-02-08 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-27 | Eingeleitet | Berenberg | Buy |
| 2020-04-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-13 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-09 | Eingeleitet | National Securities | Neutral |
| 2019-05-30 | Eingeleitet | JP Morgan | Neutral |
| 2019-05-29 | Eingeleitet | Goldman | Neutral |
| 2019-01-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-08 | Fortgesetzt | Jefferies | Buy |
| 2018-04-04 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-01-02 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-11-15 | Bestätigt | Oppenheimer | Outperform |
| 2017-11-15 | Herabstufung | Raymond James | Outperform → Mkt Perform |
Alle ansehen
Urogen Pharma Ltd Aktie (URGN) Neueste Nachrichten
UroGen Pharma at Guggenheim Summit: Strategic Advances in Biotech By Investing.com - Investing.com South Africa
Urogen Pharma (NASDAQ:URGN) General Counsel Jason Drew Smith Sells 7,479 Shares - MarketBeat
Market Sentiment Around Loss-Making UroGen Pharma Ltd. (NASDAQ:URGN) - simplywall.st
(URGN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
UroGen Pharma CMO Schoenberg sells $145k in shares - Investing.com
UroGen Pharma CMO Schoenberg sells $145k in shares By Investing.com - Investing.com South Africa
Urogen Pharma (NASDAQ:URGN) Insider Mark Schoenberg Sells 7,373 Shares - MarketBeat
UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit - Caledonian Record
Urogen Pharma (NASDAQ:URGN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Guggenheim Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $32 - 富途牛牛
Privium Fund Management B.V. Increases Stock Position in Urogen Pharma $URGN - MarketBeat
Update Recap: Is now the right time to enter UroGen Pharma LtdWeekly Risk Report & Daily Chart Pattern Signal Reports - baoquankhu1.vn
Bull Run: Can UroGen Pharma Ltd deliver consistent dividendsJuly 2025 Spike Watch & Detailed Earnings Play Alerts - baoquankhu1.vn
Responsive Playbooks and the URGN Inflection - Stock Traders Daily
Dividend Watch: Is now the right time to enter UroGen Pharma LtdJuly 2025 Setups & Growth Oriented Trading Recommendations - baoquankhu1.vn
UroGen Pharma Ltd. (URGN) Faces Securities Class Action Amid FDA - GuruFocus
URGN: Analyst Jason Kolbert Maintains 'Buy' Rating with $33 Pric - GuruFocus
Urogen Pharma (NASDAQ:URGN) Given Buy Rating at D. Boral Capital - MarketBeat
UroGen Pharma Ltd. (URGN) Stock Analysis: Investors Eye 83% Upside Amid Biotech Innovations - DirectorsTalk Interviews
Harel Insurance Investments & Financial Services Ltd. Trims Holdings in Urogen Pharma $URGN - MarketBeat
UroGen drops 20% as FDA releases docs in advance of AdCom meeting - MSN
JELMYTO shows promise in long-term cancer treatment study - MSN
Understanding the Setup: (URGN) and Scalable Risk - Stock Traders Daily
Technical Analysis: Is UroGen Pharma Ltd stock affected by interest rate hikesWeekly Trade Report & Weekly Top Stock Performers List - Bộ Nội Vụ
Urogen Pharma (NASDAQ:URGN) Stock Price Down 6.7%Here's What Happened - MarketBeat
Aug Shorts: How interest rate cuts could boost UroGen Pharma Ltd stockQuarterly Portfolio Report & Technical Pattern Based Signals - Bộ Nội Vụ
Momentum Shift: How interest rate cuts could boost UroGen Pharma Ltd stock2025 Performance Recap & Risk Controlled Daily Trade Plans - Bộ Nội Vụ
Assessing UroGen Pharma (URGN) Valuation After ZUSDURI Secures Permanent J Code - simplywall.st
Is UroGen Pharma Ltd stock ready for breakoutMarket Weekly Review & Accurate Buy Signal Notifications - Bộ Nội Vụ
Block Trades: Will UroGen Pharma Ltd stock benefit from infrastructure spending2025 Short Interest & Step-by-Step Swing Trade Plans - Bộ Nội Vụ
Why UroGen Pharma Ltd. stock appeals to analystsQuarterly Market Summary & Safe Entry Zone Identification - Улправда
Urogen Pharma (NASDAQ:URGN) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Will UroGen Pharma Ltd. stock benefit from infrastructure spendingChart Signals & Verified Swing Trading Watchlists - Улправда
Why UroGen Pharma Ltd. (UR8) stock attracts HNW investorsJuly 2025 Short Interest & Reliable Trade Execution Plans - ulpravda.ru
Is UroGen Pharma Ltd. stock oversold or undervalued2025 Market Outlook & High Win Rate Trade Tips - Улправда
What momentum indicators show for UroGen Pharma Ltd. stock2025 Key Highlights & Advanced Technical Analysis Signals - Улправда
Will UroGen Pharma Ltd. stock see insider buyingFundamental Strength Indicators & Free Unlock Rapid Growth Potential - Улправда
Multiple Insiders Sold UroGen Pharma Shares Presenting Weak Signs For Investors - simplywall.st
How UroGen Pharma Ltd. (UR8) stock trades in high volatility2026 world cup usa national team round of 32 playmakers possession football expert forecast preview - Улправда
UroGen Pharma says permanent J Code for ZUSDURI now in effect - Yahoo Finance
Urogen Pharma (NASDAQ:URGN) Shares Down 6.5%What's Next? - MarketBeat
UroGen Pharma Ltd. Announces That Adult Patients Living with Recurrent Low-Grade Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) Now Have Improved Access to an Important Therapy - marketscreener.com
UroGen Pharma (URGN) Analyst Ratings Remain Steady with Buy Rati - GuruFocus
D. Boral Capital Reiterates "Buy" Rating for Urogen Pharma (NASDAQ:URGN) - MarketBeat
Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy - GlobeNewswire
The Truth About UroGen Pharma (URGN): Is This Tiny Cancer Stock the Next Viral Game-Changer or a Tot - AD HOC NEWS
What analysts say about UroGen Pharma Ltd stockMarket Timing Techniques & Free High Velocity Capital Growth - earlytimes.in
The Technical Signals Behind (URGN) That Institutions Follow - Stock Traders Daily
URGN: Small-Cap Biotech On A Knife Edge As Traders Weigh Risk, Cash And Uro-Oncology Data - AD HOC NEWS
Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally - AOL.com
Loss-Making UroGen Pharma Ltd. (NASDAQ:URGN) Expected To Breakeven In The Medium-Term - Yahoo Finance
Finanzdaten der Urogen Pharma Ltd-Aktie (URGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Urogen Pharma Ltd-Aktie (URGN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Schoenberg Mark | Chief Medical Officer |
Feb 03 '26 |
Sale |
19.69 |
7,373 |
145,174 |
144,985 |
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):